Navigation Links
3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement
Date:5/23/2013

SHENYANG, CHINA, May 24, 2013 /PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that, at an extraordinary general meeting held today (the "EGM"), the Company's shareholders voted in favor of the proposal to authorize and approve the previously announced agreement and plan of merger dated February 8, 2013, among Decade Sunshine Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands ("Parent"), Decade Sunshine Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of Parent ("Merger Sub"), and the Company, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of April 24, 2013 (the "Amended Merger Agreement"), pursuant to which Merger Sub will be merged with and into the Company, with the Company surviving the merger as a wholly-owned subsidiary of Parent (the "Merger"), and to authorize and approve all transactions contemplated by the Amended Merger Agreement, including the Merger.  

Approximately 91.38% of the Company's total outstanding ordinary shares and voting restricted shares were voted in person or by proxy at the EGM. Of these shares voted in person or by proxy at the EGM, approximately 87.20% were voted in favor of the proposal to authorize and approve the Amended Merger Agreement and the transactions contemplated thereby, including the Merger, and approximately 87.20% were voted in favor of the proposal to authorize and approve the directors of the Company to do all things necessary to give effect to the Amended Merger Agreement. 

The parties expect to complete the Merger as soon as practicable, subject to the satisfaction or waiver of the conditions set forth in the Amended Merger Agreement.  Upon completion of the Merger, the Company will become a privately-held company and its American depository shares will no longer be listed on the NASDAQ Global Market.   

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people.  Shares trade in the form of ADSs on the NASDAQ Global Market under the ticker symbol "SSRX".  Please see www.3SBio.com for more information.

Safe Harbor Statement

This press release and related Company disclosures may include certain statements that are not descriptions of historical facts, but are forward-looking statements.  Such statements include, among others, those concerning expected benefits and costs of the proposed transaction; management plans relating to the transaction; the expected timing of various aspects of the transaction; the parties' ability to complete the transaction considering the various closing conditions, as well as all assumptions, expectations, predictions, intentions or beliefs about future events.  Forward-looking statements can generally be identified by the use of forward-looking terminology such as "anticipate," "proposed," "will," "intend," "may," "believes," "expects" or similar expressions.  Such information is based upon expectations of the Company that were reasonable when made.  Risks and uncertainties that may cause actual outcome to differ from the forward-looking statements may include: whether Parent will secure and receive full financing; whether all the closing conditions and other terms of the transaction documents will be duly complied with or fulfilled; future business decisions of various parties, and other risks and uncertainties discussed in the documents filed or to be filed with the U.S. Securities and Exchange Commission by the Company, particularly the Transaction Statement on Schedule 13E-3 and exhibits thereto.  These forward-looking statements reflect the Company's expectations as of the time of this press release.  The Company undertakes no ongoing obligation, other than that imposed by law, to update these statements.

For investor and media inquiries, please contact:   

Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: + 86 24 2581-1820
ir@3SBio.com

Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: + 852 8191-6991
ir@3SBio.com

 

 

 


'/>"/>
SOURCE 3SBio Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
2. 3SBio Inc. To Present at the DB Access Asia Conference 2012
3. 3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin
4. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
5. 3SBio Inc. Announces Changes to Its Board of Directors
6. Apexigen Announces the Filing of an IND by its Partner, 3SBio
7. 3SBio Inc. to Hold 2012 Annual General Meeting on October 10, 2012
8. 3SBio Inc. Announces Receipt of "Going Private" Proposal at $15 Per ADS
9. 3SBio Independent Committee Selects Legal Counsel in connection with Going Private Proposal
10. 3SBio Inc. Announces Unaudited Third Quarter 2012 Results
11. 3SBio Inc. Schedules Unaudited Fourth Quarter and Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
(Date:5/8/2017)... MACRA replaces the outdated sustainable growth ... reimbursement. Black Book Research crowdsource-surveyed 8,845 physician practices from ... Market for MIPS Compliance Technology is Booming ... 3 or more clinicians seek to buy Merit-Based Incentive ... magnitude of the changes, the hunt is on for ...
(Date:5/6/2017)... , May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: ... approximately 100,000 square feet to its Welch Allyn campus. ... its commitment to bring more than 100 new jobs ... Welch Allyn has maintained a significant presence for more ... these new positions, a large portion of which will ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as host and ... the series is on hiking in American. Viewers can reconnect with America as it ... of hiking. , Many consumers have looked for an inventive new place for a ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based BluSky Restoration Contractors ... its 14th Annual Clays for Kids fundraiser, to be held Friday, Sept. 22, ... , As part of BluSky’s partnership with The Adoption Exchange, BluSky will also ...
(Date:5/24/2017)... N.J. (PRWEB) , ... May 24, 2017 , ... ... Clara Maass Medical Center CEO Mary Ellen, hospital employees, and town officials to ... Belleville. , The facility was developed by Rendina as part of its ongoing ...
(Date:5/24/2017)... California (PRWEB) , ... May 24, 2017 , ... ... through innovative medical image management and interpretation, has received U.S. Food and Drug ... , Nucleus.io is a web-based, scalable and secure cloud platform for medical image ...
(Date:5/24/2017)... DC (PRWEB) , ... May 24, 2017 , ... ... Center for Global Policy Solutions is vehemently opposed to Donald Trump’s budget, “A ... formula for despair that inspires fear, demonizes the poor, marginalizes underserved populations, undermines ...
Breaking Medicine News(10 mins):